Brief: Neuren Pharmaceuticals Says Got U.S. FDA Approval For Pitt Hopkins Syndrome Ind And Phase 2 Trial
25/03/2022 01:42
March 25 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* FDA APPROVAL FOR PITT HOPKINS SYNDROME IND AND PHASE 2
TRIAL-NEU.AX
Source text for Eikon: ID:nASX1hSzPl
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union